bluebird bio Inc (BLUE) : Alpinvest Partners B.v. reduced its stake in bluebird bio Inc by 69.78% during the most recent quarter end. The investment management company now holds a total of 13,980 shares of bluebird bio Inc which is valued at $794,064 after selling 32,284 shares in bluebird bio Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.bluebird bio Inc makes up approximately 1.33% of Alpinvest Partners B.v.’s portfolio.
Other Hedge Funds, Including , New York State Common Retirement Fund reduced its stake in BLUE by selling 28,615 shares or 14.55% in the most recent quarter. The Hedge Fund company now holds 168,000 shares of BLUE which is valued at $9,542,400. bluebird bio Inc makes up approx 0.01% of New York State Common Retirement Fund’s portfolio.Td Asset Management Inc reduced its stake in BLUE by selling 300 shares or 0.72% in the most recent quarter. The Hedge Fund company now holds 41,200 shares of BLUE which is valued at $2,381,360.Alps Advisors Inc boosted its stake in BLUE in the latest quarter, The investment management firm added 10,368 additional shares and now holds a total of 51,898 shares of bluebird bio Inc which is valued at $2,912,516. bluebird bio Inc makes up approx 0.03% of Alps Advisors Inc’s portfolio.Simplex Trading reduced its stake in BLUE by selling 17,308 shares or 89.97% in the most recent quarter. The Hedge Fund company now holds 1,929 shares of BLUE which is valued at $92,766. bluebird bio Inc makes up approx 0.01% of Simplex Trading’s portfolio. Fox Run Management L.l.c. sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 8,500 shares of BLUE which is valued $408,765.
bluebird bio Inc closed down -2.97 points or -5.24% at $53.73 with 12,57,212 shares getting traded on Friday. Post opening the session at $56.68, the shares hit an intraday low of $53.28 and an intraday high of $56.68 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, bluebird bio Inc reported $-1.59 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-1.50. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $2.01 million. The company’s revenue was down -68.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-1.57 EPS.
Many Wall Street Analysts have commented on bluebird bio Inc. Shares were Reiterated by Maxim Group on Aug 4, 2016 to “Buy” and Lowered the Price Target to $ 85 from a previous price target of $105 .bluebird bio Inc was Initiated by Cantor Fitzgerald to “Hold” on Jun 3, 2016.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.